medigraphic.com

2003, Number 3

<< Back Next >>

Rev Fac Med UNAM 2003; 46 (3)

Estrogen cardiovascular protection mechanisms

Franco Y, Mendoza-Fernández V, Lemini C

Language: Spanish
References: 52
Page: 101-108
PDF size: 79.51 Kb.


ABSTRACT

A number of clinical studies have shown that cardiovascular diseases are more common among men than in women at reproductive ages. The protection in women has been associated with estrogens blood levels. When hormones production declines in the menopause, the susceptibility is similar to that observed in men. Also, replacement hormone therapy diminishes the risk for cardiovascular diseases in postmenopausal women. These observations have supported the idea that estrogens play a cardioprotective role for women before the physiological menopausal state. However, the mechanism through which hormones modify the cardiovascular reactivity and the elements that induce changes such are still not well known. Estrogens participates on lipoprotein metabolism, blood coagulation, induction of relaxing factors from the endothelium cells and the modification of blood vessels smooth muscle reactivity. These events play an important cardioprotective role. In this work we show updated information about how estrogens acts upon the cardiovascular system and produced protective effects.


REFERENCES

  1. Fritsch MK, Murdoch FE. Estrogens, Progestins, and Oral Contraceptives. In: Brody TM, Larner J, Minneman K, Neu HC, eds. Human Pharmacology molecular to clinical. 2ª ed. New York, NY 1994; 482-500.

  2. Johansson BW, Kaij L, Kullander S, Lennér HC, Svanberg L, Astedt B. On some late effects of bilateral oophorectomy in the age range 15-30 years. Acta Obstet Gynecol Scand 1975; 54: 449-461.

  3. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids, 1990; 55: 330-351.

  4. Zarate TA. La versatilidad de los estrógenos se aprovecha en el tratamiento de la posmenopausia. Gac Med Mex 1999; 135(3): 341-344.

  5. Stampfer M, Colditz G. Estrogen replacement therapy: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.

  6. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 1997; 37: 477-515.

  7. Bilsel AS, et al. Long-term effect of 17beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC. Thromb Res 2000; 99: 173-178.

  8. Wakasugi M, Noguchi T, Kazama YI, Kanemaru Y, Onaya T. The effects of sex hormones on the synthesis of prostacyclin (PGI2) by vascular tissues. Prostaglandins 1989; 37: 401-410.

  9. Polderman KH, Steouwer CDA, van Kamp GP, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-432.

  10. Valverde MA, Rojas P, Amigo J, Cosmelli D, Orio P, Sahamonde MI, Mann GE, Vergara C, Latorre R. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the b Subunit. Science 1999; 285: 1929-1931.

  11. Zhang, F, Ram JL, Standley PR, Sowers JR. 17 beta-estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol 1994; 266: C975-980.

  12. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-331.

  13. Tikkanen MJ, Kikkila EA, Kussi T, Sipinen S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab1982; 54: 1113-7.

  14. Bowman WC, Rand MJ. Regulación de la composición de líquidos corporales y lípidos plasmáticos. En: Farmacología. Bases Bioquímicas y Patológicas. Aplicaciones Clínicas. Segunda edición. Interamericana, Eds. México 1984: 28.1-28.36.

  15. Guetta V, Cannon III RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996; 93: 1928-1937.

  16. Bush TL, Barret-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran Cm, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75(6): 1102-9.

  17. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994; 35: 2083-2093.

  18. Izaguirre AR. Mecanismos Hemostáticos. En: Fundamentos de Hematología. Ruiz Argüellles GJ., eds. 1ª. Edición. Ed. Panamericana. México 1995: 190-204.

  19. Gottsäter A, Rendell M, Hulthén UL, Berntorp E, Mattiasson I. Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Inter Med 2001; 249: 237-246.

  20. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO 3rd. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336(10): 683-90.

  21. Luyer P, Khosla S, Owen WG, Miller M. Prospective Randomized Study of Effects of Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in Postmenopausal Women. J Clin Endoc and Metab 2001; 86(8): 3629-3634.

  22. Emms H, Lewis GP. Sex and hormonal influences on platelet sensititvity and coagulation in the rat. Br J Pharmacol 1985; 86: 557-563.

  23. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, Fantoni A. Estrogen induction and contact phase activation of human factor XII. Steroids 1996; 61: 270-276.

  24. Lemus AE, Jaimez R, Lemini C, Menjivar M, Silva G, Rubio-Póo C, Valenzuela F, Larrea F. Estrogen effects of the synthetic aminoestrogens 17b-(5-hydroxy-1-pentylamino)-1,3,5(10)-estratrien-3-ol (pentolame). Steroids 1998; 63: 433-438.

  25. Manzano-García A, González-Llaven J, Jaimez R, Franco Y, Avila ME, Rubio-Póo C, Lemini C. Changes on hemostatic parameters induced by 17b-estradiol, ethinylestradiol, and the 17b-aminoestrogen pentolame in the male Wistar rat. Steroids 2002; 67: 1129-1135.

  26. Krasinki K, Spyridopoulos I, Ashara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997; 95: 1768-1772.

  27. Mendelsohn ME. Genomic and Nongenomic Effects of Estrogen in the Vasculature. Am J Cardiol 2002; 90(suppl): 3F-6F.

  28. Flavahan NA, Shimokawa H, Vanhoutte PM. Inhibition of endothelium-dependent relaxations by phorbol myristate acetate in canine arteries: role of a pertussis toxin-sensitive G-protein. J Pharmacol Exp Ther 1991; 256: 50-55.

  29. Lonning PE, Dowsett M, Jacobs S, Schem B, Hardy J, Powles TJ. Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. J Steroid Biochem 1989; 34: 551-3.

  30. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992; 89: 11259-11263.

  31. Van Buren GA, Yang DS, Clark KE. Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester, and inhibitor of nitric oxide synthesis. Am J Obstet Gynecol 1992; 167: 828-833.

  32. Gisclard V, Flavahan NA. Vanhoutte PM. Alpha adrenergic responses of blood vessels of rabbits after ovariectomy and administration of 17 beta-estradiol. J Pharmacol Exp Ther 1987; 240: 466-470.

  33. Miller VM, Vanhoutte PM. 17beta-estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. Am J Physiol 1990; 258: R1502-R1507.

  34. Yangisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.

  35. Emori T, Hirata Y, Ohta K, Shichiri M, Marumo F. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem Biophys Res Commun. 1989; 160: 93-100.

  36. Schini VB, Hendrickson H, Heublein DM, Burnett Jr JC, Vanhoutte PM. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol 1989; 165: 333-334.

  37. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 587-590.

  38. Bossu JL, Elhamdami A, Feltz A, Tanzi F, Aunis D. Voltage-gated Ca entry in isolated bovine capillary endothelial cells: evidence of a new type of Bay K8644-sensitive channel. Pflugers Arch 1992; 420: 200-207.

  39. Muck AO, Seeger H, Korte K, Lippert TH. The effect of 17-beta-estradiol and endothelin 1 on prostacyclin and thromboxane production in human endothelial cell cultures. Clin Exp Obstet Gynecol 1993; 20: 203-206.

  40. Davis MG, Hagen PO. The vascular endothelium. A new horizon. Ann Surg 1993; 218: 593-609.

  41. Miller VM, Vanhoutte PM. 17beta-estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. Am J Physiol 1990; 258: R1502-R1507.

  42. Karas RH, Paterson BL. Human vascular smooth muscle cells contain functional estrogen receptor. Ciculation 1994; 89: 1943-1950.

  43. Weisz A, Bresciani F. Estrogen induces expression of c-fos and c-myc protooncogenes in rat uterus. Mol Endo 1988; 2: 816-824.

  44. Orimo A, Inoue S, Ikegami A, Hosoi T, Masahiro A, Yasuyoshi O, Masami M, Orimo H. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Com 1993; 95(2): 730-736.

  45. Beale C, Collins P. Estrogen and cardiovascular dynamics. Sem Reprod Endocrinol 1996; 14(1): 71-77.

  46. Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995; 99(2): 119-22.

  47. Andersen HL, Weis JU, Fjalland B, Korsgaard N. Effects of acute and long-term treatment with 17b-estradiol on the vasomotor responses in the rat aorta. British J Pharmacol 1999; 126: 159-168.

  48. Xiao-Jian Y. Voltage-Gated K+ currents regulate resting membrane potential and [Ca2+]i in pulmonary arterial miocytes. Circ Res 1995; 77: 370-378.

  49. Harder DR, Coulson PB. Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol 1979; 100: 375-382.

  50. Nakajima T, Kitazawa T, Hamada E, Hazama H, Omata M, Kurachi Y. 17b-estradiol inhibits the voltage-dependent L-type Ca2+ currents in aortic smooth muscle cells. European Journal of Pharmacology 1995; 294: 625-635.

  51. Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, MacLeod KT. Effect of 17 beta-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992; 106: 739-745.

  52. Andersen HL, Weis JU, Fjallan B y Korsgaard N. Effects of acute and long-term treatment with 17b-estradiol on the vasomotor responses in the rat aorta. British J Pharmacol 1999; 126: 159-168.




2020     |     www.medigraphic.com